drugset / Trial / NCT01064817

PRM-151 in the Prevention of Scarring Following Trabeculectomy

NCT01064817

Phase 2 Completed 124 enrolled Hoffmann-La Roche
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study will assess the safety and tolerability of PRM-151 administered as a subconjunctival injection and explore the effect of PRM-151 on various correlates of the wound healing process that occurs in the eye after glaucoma filtration surgery.

Timeline

Start
2010-06-14
Primary completion
2012-04-30
Completion
2012-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Zinpentraxin Alfa Protein / enzyme biologic 2 mg Other

Indications